Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash & Equivalents: 2016-2025

Historic Cash & Equivalents for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $166.4 million.

  • Akebia Therapeutics' Cash & Equivalents rose 389.27% to $166.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.4 million, marking a year-over-year increase of 389.27%. This contributed to the annual value of $51.9 million for FY2024, which is 20.84% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Cash & Equivalents of $166.4 million as of Q3 2025, which was up 21.22% from $137.3 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Cash & Equivalents registered a high of $252.8 million during Q1 2021, and its lowest value of $34.0 million during Q3 2024.
  • Its 3-year average for Cash & Equivalents is $71.3 million, with a median of $51.9 million in 2024.
  • In the last 5 years, Akebia Therapeutics' Cash & Equivalents slumped by 67.87% in 2023 and then surged by 389.27% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Cash & Equivalents (Quarterly) stood at $149.8 million in 2021, then plummeted by 39.61% to $90.5 million in 2022, then crashed by 52.55% to $42.9 million in 2023, then increased by 20.84% to $51.9 million in 2024, then skyrocketed by 389.27% to $166.4 million in 2025.
  • Its Cash & Equivalents was $166.4 million in Q3 2025, compared to $137.3 million in Q2 2025 and $113.4 million in Q1 2025.